KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Change in Accured Expenses (2018 - 2025)

Moderna (MRNA) has disclosed Change in Accured Expenses for 8 consecutive years, with $131.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Accured Expenses rose 140.68% to $131.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$6.0 million, a 98.44% increase, with the full-year FY2025 number at -$6.0 million, up 98.44% from a year prior.
  • Change in Accured Expenses was $131.0 million for Q4 2025 at Moderna, down from $258.0 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $654.0 million in Q3 2023 to a low of -$618.0 million in Q2 2023.
  • A 5-year average of $64.9 million and a median of $93.0 million in 2023 define the central range for Change in Accured Expenses.
  • Biggest YoY gain for Change in Accured Expenses was 4650.0% in 2021; the steepest drop was 11000.0% in 2021.
  • Moderna's Change in Accured Expenses stood at $389.0 million in 2021, then crashed by 33.68% to $258.0 million in 2022, then plummeted by 74.03% to $67.0 million in 2023, then crashed by 580.6% to -$322.0 million in 2024, then surged by 140.68% to $131.0 million in 2025.
  • Per Business Quant, the three most recent readings for MRNA's Change in Accured Expenses are $131.0 million (Q4 2025), $258.0 million (Q3 2025), and -$428.0 million (Q2 2025).